milk thistle 
We Have Found 64 Papers
Bird Score
Ingredients
Main Function
Fatty Liver
Hepatitis
Non-alcoholic Fatty Liver Disease
Liver (hepatitis)
Blood Glucose
Nonalcoholic Fatty Liver Disease
Liver (liver Neoplasms)
Obesity
Diabetes
Nonalcoholic Fatty Liver Disease (nafld)
Chronic Liver Diseases
Non-alcoholic Steatohepatitis (nash)
Breast Carcinoma
Colorectal Cancer
Parkinson’s Disease (pd)
Intestinal Mucosa
Stress 
Alzheimer's Disease
Lung Carcinoma
Hiv And Hepatitis C Virus (hcv)
Skin
Cancer
Hcv
Non-alcoholic Steatohepatitis
Dementia
Women's Monopause
Ovarian Cancer
Hepatitis 
Liver (non-alcoholic Fatty Liver)
Urination
Functionalityabstract Purpose: Hepatocellular Carcinoma
Bioactive Compound
Type of Study
Mechanism Keyword
  • Sirt1/ampk Pathway

  • Through Slit-2/robo-1 Pathway

  • Jnk Phosphorylation

  • Activation Of Ampkα

  • Associated Decrease Of Hiv Replication And Increase Of Cd4+ Cell Counts

  • Inhibits The Expression Of Gsk-3β

  • Hepatoprotection Seems To Involve The Inhibition Of Oxidative Stress And Protein Nitrosylation, Preventing Activation Of Hepatic Fibrosis Mechanisms

  • By Decreasing The Er Stress Proteins Grp78 And Xbp-1

  • By Reducing The Expression Of Mir-122 And Inhibiting The Expression Of Mir-122

  • Silymarin-induced Alleviation Of Inflammatory Response

  • Inhibition Of The O-glcnacylation-dependent Nf-κb-signaling Pathway

  • Regulating The Irs-1/pi3k/akt Pathway

  • By Increasing Bax And Decreasing Bcl-2 Protein Expression, And Activation Of Caspase-9 And Caspase-3

  • By Modulating Antioxidant Enzyme Activity, Reduced Glutathione, And Protein Carbonyl Levels.

  • Upregulated Erα And β Levels And Reduced The Level Of 8-ohdg In Glp-1-positive Cells

  • Targeting Hif-1 Activity.

  • Ache Inhibitory Activities

  • Negative Regulators Of The Jak-stat Pathway

  • Ifn Action

  • Inhibited Cdk2, Cdk4, And Cdc2 Kinase Activity

Choice Keyword
  • milk thistle :
Clear All
Top10 List (64)   버드 스코어링에 의한 리스트
NO Bird Score Title
number1 87.14 Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient
number1 87.14 Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
number1 87.14 Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men
number1 85.71 A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis
number1 85.71 A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
number1 85.71 A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
number1 85.71 Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial
number1 85.71 Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
number1 85.71 Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial
number1 84.29 A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis
82.14 Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C
82.14 Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients
82.14 Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
81.29 Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells
80.71 Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease
80.71 Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study
80.71 A pilot and feasibility study on the effects of naturopathic botanical and dietary interventions on sex steroid hormone metabolism in premenopausal women
80.71 Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
79.29 The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease
77.86 Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C
77.86 Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C
64.07 Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin
59.07 Inhibition of HCV 3a core gene through Silymarin and its fractions
58.04 Phytochemical analysis, molecular docking and antiamnesic effects of methanolic extract of Silybum marianum (L.) Gaertn seeds in scopolamine induced memo..
57.64 Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway
57.64 Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway
56.93 Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications fo..
56.75 Silibinin improves L-cell mass and function through an estrogen receptor-mediated antioxidative mechanism
56.61 Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty ac..
56.61 Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty ac..
56.21 Protective Effect of Silybum marianum and Silibinin on Endothelial Cells Submitted to High Glucose Concentration
55.32 Effect of Silymarin in Pdx-1 expression and the proliferation of pancreatic β-cells in a pancreatectomy model
55.32 Effect of Silymarin in Pdx-1 expression and the proliferation of pancreatic β-cells in a pancreatectomy model
55.18 Silibinin Ameliorates O-GlcNAcylation and Inflammation in a Mouse Model of Nonalcoholic Steatohepatitis
55.18 Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathw..
54.79 Inhibition of HCV 3a core gene through Silymarin and its fractions
53.89 Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice
53.89 Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice
53.75 Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
53.75 Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
53.75 Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
53.75 Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
53.36 Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors
53.18 Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice
53.18 Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis
53.18 Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis
53.18 Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An in vitro and in vivo study
51.93 Antioxidant, anti-collagenase and anti-elastase activities of Phyllanthus emblica, Manilkara zapota and silymarin: an in vitro comparative study for anti..
51.75 Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a rel..
51.75 Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice
51.75 Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver
51.75 Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice
48.89 Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats
48.89 Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal tra..
48.89 Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan
48.89 Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats
48.36 The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin
47.46 Therapeutic Effects of Milk Thistle (Silybum marianum L.) and Artichoke (Cynara scolymus L.) on Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Rats
47.46 Injectable and biodegradable poly(organophosphazene) gel containing silibinin: its physicochemical properties and anticancer activity
47.46 Silymarin inhibits the development of diet-induced hypercholesterolemia in rats
47.46 Therapeutic Effects of Milk Thistle (Silybum marianum L.) and Artichoke (Cynara scolymus L.) on Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Rats
46.04 Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model
43.89 Silibinin Ameliorates Formaldehyde-Induced Cognitive Impairment by Inhibiting Oxidative Stress
42.14
Basic Info
Extraction Info
Study Info

cancle